Microbot Medical Expands Government Reach with Lovell Partnership
Event summary
- Microbot Medical partners with Lovell Government Services to expand access to its LIBERTY® Endovascular Robotic System for federal healthcare systems, including the Veterans Health Administration and Military Health System.
- Lovell will add the LIBERTY System to its Federal Supply Schedule (FSS) contract, with activation expected in Q3 2026.
- The partnership aims to streamline procurement for government agencies while meeting SDVOSB (Service-Disabled Veteran-Owned Small Business) procurement goals.
- Lovell serves over 170 medical centers and numerous outpatient clinics, averaging over 200 peripheral endovascular cases annually per site.
The big picture
This partnership aligns with broader trends in government healthcare procurement, where streamlined access and compliance with SDVOSB goals are increasingly prioritized. By integrating with Lovell’s extensive network, Microbot Medical positions itself to capture a significant share of federal endovascular procedures, a market segment with high growth potential due to aging veteran populations and advancements in minimally invasive technologies.
What we're watching
- Procurement Momentum
- The pace at which the LIBERTY System gains traction within federal healthcare systems will signal adoption rates and revenue potential.
- Government Contracting
- Whether Microbot can leverage this partnership to secure additional federal contracts and expand its market reach.
- Competitive Positioning
- How this move affects Microbot’s standing against competitors in the endovascular robotic space.
Related topics